000118704 001__ 118704 000118704 005__ 20230519145526.0 000118704 0247_ $$2doi$$a10.3390/cancers13215278 000118704 0248_ $$2sideral$$a126835 000118704 037__ $$aART-2021-126835 000118704 041__ $$aeng 000118704 100__ $$0(orcid)0000-0003-4712-9891$$aSerrablo A.$$uUniversidad de Zaragoza 000118704 245__ $$aVascular resection in perihilar cholangiocarcinoma 000118704 260__ $$c2021 000118704 5060_ $$aAccess copy available to the general public$$fUnrestricted 000118704 5203_ $$aAmong the cholangiocarcinomas, the most common type is perihilar (phCC), accounting for approximately 60% of cases, after which are the distal and then intrahepatic forms. There is no staging system that allows for a comparison of all series and extraction of conclusions that increase the long-term survival rate of this dismal disease. The extension of the resection, which theoretically depends on the type of phCC, is not a closed subject. As surgery is the only known way to achieve a cure, many aggressive approaches have been adopted. Despite extended liver resections and even vascular resections, margins are positive in around one third of patients. In the past two decades, with advances in diagnostic and surgical techniques, surgical outcomes and survival rates have gradually improved, although variability is the rule, with morbidity and mortality rates ranging from 14% to 76% and from 0% to 19%, respectively. Extended hepatectomies and portal vein resection, or even right hepatic artery reconstruction for the left side tumors are frequently needed. Salvage procedures when arterial reconstruction is not feasible, as well as hepatopancreatoduodenectomy, are still under evaluation too. In this article, we discuss the aggressive surgical approach to phCC focused on vascular resection. Disparate results on the surgical treatment of phCC made it impossible to reach clear-cut conclusions. © 2021 by the authors. Licensee MDPI, Basel, Switzerland. 000118704 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/ 000118704 590__ $$a6.575$$b2021 000118704 591__ $$aONCOLOGY$$b60 / 245 = 0.245$$c2021$$dQ1$$eT1 000118704 592__ $$a1.349$$b2021 000118704 593__ $$aOncology$$c2021$$dQ1 000118704 593__ $$aCancer Research$$c2021$$dQ1 000118704 594__ $$a5.8$$b2021 000118704 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000118704 700__ $$aSerrablo L. 000118704 700__ $$aAlikhanov R. 000118704 700__ $$aTejedor L. 000118704 7102_ $$11013$$2090$$aUniversidad de Zaragoza$$bDpto. Cirugía$$cÁrea Cirugía 000118704 773__ $$g13, 21 (2021), 5278 [12 pp]$$pCancers$$tCancers$$x2072-6694 000118704 8564_ $$s899361$$uhttps://zaguan.unizar.es/record/118704/files/texto_completo.pdf$$yVersión publicada 000118704 8564_ $$s2690021$$uhttps://zaguan.unizar.es/record/118704/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000118704 909CO $$ooai:zaguan.unizar.es:118704$$particulos$$pdriver 000118704 951__ $$a2023-05-18-15:26:18 000118704 980__ $$aARTICLE